• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveil at 2026 AACR

    FIRSTWORD PHARMA

    Innocare Achieves First Annual Profit In 2025 Results

    GLOBENEWSWIRE

    Priority Review for InnoCare`s Zurletrectinib in Pediatric Tumors

    GLOBENEWSWIRE

    Innocare Pharma Advances Oral Lupus Drug To Phase II Trial

    INDPHARMAPOST

    Innocare Greenlights Phase II/III Trial For Soficitinib

    GLOBENEWSWIRE

    InnoCare`s Orelabrutinib Meets Primary Endpoint in Phase 2b SLE

    GLOBENEWSWIRE

    Innocare Hits Phase IIb Endpoint With Orelabrutinib For SLE

    GLOBENEWSWIRE

    Innocare Approves Next-Gen TRK Inhibitor Zurletrectinib In China

    GLOBENEWSWIRE

    Innocare Showcases Orelabrutinib In 20+ Studies At ASH Meeting

    GLOBENEWSWIRE

    InnoCare Announces 1st Patient Dosed in Ph 2 Trial of Soficitinib

    GLOBENEWSWIRE

    Innocare Initiates Clinical Trial For ADC ICP-B794 In China

    GLOBENEWSWIRE

    InnoCare`s HIBRUKA Approved for Zone Lymphoma in Singapore

    GLOBENEWSWIRE

    InnoCare Starts BCL2 Inhibitor Mesutoclax Trial for BTKi MCL

    GLOBENEWSWIRE

    InnoCare Greenlights Clinical Trial for Novel ADC ICP-B794

    BUSINESSWIRE

    InnoCare’s Minjuvi Combo Approved in China

    BUSINESSWIRE

    InnoCares Mesutoclax Gets Breakthrough Therapy from China`s NMPA

    BUSINESSWIRE

    InnoCare`s Zurletrectinib Gets Priority Review from China`s NMPA

    BUSINESSWIRE

    InnoCare Releases 2024 Results and Business Highlights

    BUSINESSWIRE

    InnoCare Doses First Patient In Ph 3 ICP-248 Trial For CLL/SLL

    BUSINESSWIRE

    InnoCare Gets China Nod For Ph III Study Of ICP-248 In CLL/SLL

    BUSINESSWIRE

    InnoCare & KeyMed Announce Agreement for Bispecific Antibody

    BUSINESSWIRE

    Zurletrectinib Shows Strong Activity Against NTRK Fusion-Positive Tumors

    BUSINESSWIRE

    InnoCare`s Tafasitamab BLA Accepted For DLBCL Treatment In China

    BUSINESSWIRE

    InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program

    BUSINESSWIRE

    InnoCare and Keymed Jointly Announce Subject Dosed in Trial of CCR8 Monoclonal Antibody ICP-B05

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.